What to expect when participating in clinical trials

When you volunteer for a clinical trial, it’s essential to manage your expectations, understanding both the potential benefits and risks involved. Awareness of the side effects associated with clinical trials can better prepare you for the experience. Although clinical trials are generally safe, there is no absolute guarantee that you won’t experience adverse effects.

Side effects in clinical trials occur when a new treatment interacts with the body in unintended ways. Doctors classify these effects into five grades, with higher grades indicating more severe reactions. Grade 1 effects are mild, while Grade 2 can impact daily life. Grades 3, 4, and 5 are more serious, often prompting medical intervention.

The purpose of clinical trials is not just to evaluate the effectiveness of new treatments but also to assess their safety. The likelihood and nature of side effects depend on how the drug interacts with your body and its specific characteristics. Common side effects reported by participants include headaches, coughing, discomfort, and pain. These effects are meticulously recorded to provide evidence of the drug’s safety and to inform future patients of potential risks.

Side effects are identified through various methods, including patient reports, physical exams, and blood tests. Doctors regularly check for asymptomatic side effects that participants might not notice. These effects are recorded from the first phase of the trial, with more attention given to those in grades 3 and above due to their potential seriousness.

If you experience side effects during a trial, it’s crucial to report them immediately. You should contact the nursing staff or report directly to the on-duty staff if you’re in a residential trial. If necessary, a doctor will examine you, especially if the side effects appear severe. At FluCamp, for instance, staff closely monitor all participants to ensure early detection of side effects, enhancing the safety of every volunteer.

The safety of clinical trial participants is a top priority. Several measures are in place to ensure this, starting with the approval process for trials, which involves rigorous scrutiny by regulatory bodies such as the Medicines and Healthcare Products Regulatory Agency (MHRA). These bodies not only approve but also monitor the trials to ensure adherence to safety protocols.

Informed consent is a crucial aspect of participation. Before joining a trial, clinical staff provide a detailed overview of the study, including its purpose, the drugs involved, and potential risks. This process ensures that you fully understand what you are agreeing to and allows you to ask any questions before giving your consent.

Additionally, a comprehensive screening process determines whether you are eligible to participate. This process considers factors like age, weight, and medical history to ensure the trial is safe for you. If you have conditions that could be exacerbated by the treatment, you may be excluded to reduce risk. FluCamp, for example, follows a strict screening protocol to ensure all safety measures are met.

While participating in a clinical trial may involve some risk of side effects, facilities like FluCamp mitigate these risks through vigilant monitoring and prompt intervention, ensuring your safety throughout the process.

Understanding the potential risks and the measures in place to protect you can help you make an informed decision about participating in a clinical trial.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from

    hVIVO plc

    The importance of Clinical Trial Monitoring

    Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring

    hVIVO plc

    The future of vaccine development through human challenge trials

    Testing new treatments and vaccines often requires years, if not decades, to gather sufficient data. In response, scientists are turning to a more direct approach that involves deliberately infecting volunteers with potentially deadly pathogens. A notable

    hVIVO plc

    The impact of Clinical Trial results on medical advancements

    Clinical trials play a pivotal role in advancing the medical industry by allowing new treatments and interventions to be rigorously tested for both effectiveness and safety. Understanding how clinical trial data is used is essential to

    hVIVO plc

    Hvivo reports significant growth in earnings and revenue

    Hvivo, previously known as Open Orphan, saw a significant increase in earnings during the first six months of the year, marking a 67.6% rise. Earnings before interest, taxes, depreciation, and amortisation reached £8.7 million (€10.32 million),

    hVIVO plc

    hVIVO reports strong first half, delivering record revenues and margins

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2024.